Wells Fargo Maintains Underweight on Aptiv, Lowers Price Target to $112
Wells Fargo analyst Colin Langan maintains Aptiv (NYSE:APTV) with a Underweight and lowers the price target from $124 to $112.
Wells Fargo Maintains Equal-Weight on Range Resources, Raises Price Target to $26
Wells Fargo analyst Nitin Kumar maintains Range Resources (NYSE:RRC) with a Equal-Weight and raises the price target from $21 to $26.
DZ Bank Downgrades Facebook to Hold, Announces $350 Price Target
DZ Bank analyst Ingo Wermann downgrades Facebook (NASDAQ:FB) from Buy to Hold and announces $350 price target.
Barclays Maintains Equal-Weight on Olin, Raises Price Target to $54
Barclays analyst Michael Leithead maintains Olin (NYSE:OLN) with a Equal-Weight and raises the price target from $51 to $54.
Barclays Maintains Equal-Weight on Altice USA, Lowers Price Target to $24
Barclays analyst Kannan Venkateshwar maintains Altice USA (NYSE:ATUS) with a Equal-Weight and lowers the price target from $36 to $24.
JMP Securities Maintains Market Outperform on Stifel Financial, Raises Price Target to $87
JMP Securities analyst Devin Ryan maintains Stifel Financial (NYSE:SF) with a Market Outperform and raises the price target from $84 to $87.
JMP Securities Maintains Market Outperform on KKR & Co, Raises Price Target to $83
JMP Securities analyst Devin Ryan maintains KKR & Co (NYSE:KKR) with a Market Outperform and raises the price target from $82 to $83.
JMP Securities Maintains Market Perform on Goldman Sachs Group, Raises Price Target to $450
JMP Securities analyst Devin Ryan maintains Goldman Sachs Group (NYSE:GS) with a Market Perform and raises the price target from $440 to $450.
Mizuho Maintains Buy on Enterprise Prods Partners, Raises Price Target to $29
Mizuho analyst Gabriel Moreen maintains Enterprise Prods Partners (NYSE:EPD) with a Buy and raises the price target from $28 to $29.
Mizuho Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to $9
Mizuho analyst Difei Yang maintains Concert Pharmaceuticals (NASDAQ:CNCE) with a Buy and lowers the price target from $13 to $9.